Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.…
Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation
Artiva Biotherapeutics (NASDAQ: ARTV) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 134 employees.
The shares were at 3.780 USD on 20 November 2026, up 3.3% over 52 weeks. Its 52-week range is 2.960 USD to 14.53 USD: the price is 74.0% below the high and 27.7% above the low.
Its market capitalisation is 186.85M USD.
Artiva Biotherapeutics reports return on equity of -76.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 309.93M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 31 March 2027.